Form 4: Incyte Corp Executive Steven H. Stein Reports Stock Transaction

Executive Vice President and Chief Medical Officer of Incyte Corp, Steven H. Stein, reports the disposal of 10,692 shares to cover tax obligations.

Summary

• Steven H. Stein, an Executive Vice President and Chief Medical Officer at Incyte Corp, reported a transaction involving the company's common stock.
• On January 15, 2025, 10,692 shares were disposed of to cover tax withholding obligations.
• The shares were sold at a price of $72.46 per share.
• Following the transaction, Mr. Stein beneficially owns 79,319 shares of Incyte Corp common stock.
• This includes 64,408 shares that are issuable through previously reported restricted stock units and earned performance shares that have not yet vested.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing of a stock transaction, which is neither positive nor negative in itself. It is a neutral event.

Industry Context

This is a routine filing related to stock transactions by company executives, which is common in publicly traded companies. It does not indicate any specific trend or event in the pharmaceutical industry.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and this transaction is consistent with typical executive stock transactions.
• The sale of shares to cover tax obligations is a common occurrence when restricted stock units or performance shares vest.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale of shares by an executive to cover tax obligations.

Key Dates

Keywords

Incyte Corp, stock transaction, Form 4, insider trading, executive, Steven H. Stein, share disposal, tax withholding, restricted stock units, performance shares